About the Company
We do not have any company description for MiNK Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on MiNK Therapeutics, Inc.
New Strong Sell Stocks for August 22nd
List today: MiNK Therapeutics, Inc. INKT is a clinical stage biotechnology company pioneering the discovery, development, and ...
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 14, 2025 MiNK Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1 ...
MiNK Therapeutics Reports Q2 2025 Milestones and Financials
Mink Therapeutics, Inc. ( ($INKT) ) has released its Q2 earnings. Here is a breakdown of the information Mink Therapeutics, Inc. presented to its ...
MiNK Therapeutics, Inc. to Announce Fourth Quarter and Year ... - Nasdaq
MiNK Therapeutics, Inc. has announced that it will release its financial results for the fourth quarter and year-end 2024 on March 18, 2025, prior to market opening.
MiNK Therapeutics, Inc. (INKT) Q4 2023 Earnings Call Transcript
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Conference Call March 21, 2024 8:30 AM ETCompany ParticipantsZack Armen - Head, Investor ...
All You Need to Know About MiNK Therapeutics, Inc. (INKT) Rating ...
MiNK Therapeutics, Inc. (INKT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MiNK Therapeutics, Inc. Announces Pricing of Initial Public Offering
--MiNK Therapeutics, Inc., a clinical stage biotechnology company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell ...
MiNK Therapeutics, Inc. (INKT) Upgraded to Strong Buy: Here's What You ...
MiNK Therapeutics, Inc. (INKT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near ...
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript
MiNK Therapeutics, Inc. (NASDAQ: INKT) Q4 2023 Earnings Call Transcript March 21, 2024 MiNK Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.16 EPS, expectations were $-0.15.
MiNK Therapeutics, Inc. (INKT) Q3 2023 Earnings Call Transcript
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2023 Earnings Call November 9, 2023 8:30 AM ETCompany ParticipantsZack Armen – Head, Investor RelationsJennifer ...
Similar Companies
Loading the latest forecasts...